Loading…
Current Immunotherapies for Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is the most common and aggressive malignant tumor found in the central nervous system. Currently, standard treatments in the clinic include maximal safe surgical resection, radiation, and chemotherapy and are mostly limited by low therapeutic efficiency correlated with...
Main Authors: | Huang, Boyuan, Li, Xuesong, Li, Yuntao, Zhang, Jin, Zong, Zhitao, Zhang, Hongbo |
---|---|
Format: | Online Article Text |
Language: | English |
Published: |
Frontiers Media S.A.
2021
|
Subjects: | |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986847/ https://www.ncbi.nlm.nih.gov/pubmed/33767690 http://dx.doi.org/10.3389/fimmu.2020.603911 |
Similar Items
-
Advances in Immunotherapy for Glioblastoma Multiforme
by: Huang, Boyuan, et al.
Published: (2017) -
Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies
by: Huang, Boyuan, et al.
Published: (2023) -
Advances in immunotherapy for glioblastoma multiforme
by: Mahmoud, Ahmad Bakur, et al.
Published: (2022) -
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
by: Pearson, Joshua R. D., et al.
Published: (2020) -
An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas
by: Zhang, Hongbo, et al.
Published: (2020)